A comprehensive comparison of third generation epidermal growth factor receptor tyrosine kinase inhibitors in the treatment efficacy and adverse events: A Bayesian meta-analysis
Background: It is a challenge for clinicians to choose the optimal third generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs) treatment for individual patients. In this meta-analysis we compare the efficacy of five third-generation EGFR-TKIs, as first-line and second-line therapies for non-small c...
Saved in:
| Main Authors: | Jinyu Yu, PhD, Hanyu Wu, BS, Lu Yang, MD, Wei Liu, PhD, Baoshan Cao, MD, Baosheng Liang, PhD, Yangchun Gu, MD |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
KeAi Communications Co., Ltd.
2025-09-01
|
| Series: | Global Medical Genetics |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2699940425000657 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Data mining and safety analysis of FGFR tyrosine kinase inhibitors based on the FAERS database
by: Ping Li, et al.
Published: (2025-07-01) -
Proteomic Profiling Reveals TPR and FGA as Predictive Serum Biomarkers of Relapse to First- and Second-Generation EGFR-TKIs in Advanced Lung Adenocarcinoma
by: Pritsana Raungrut, et al.
Published: (2025-06-01) -
Editorial: EGFR-TKIs for lung cancer treatment: development, application, and side effects
by: Qinglin Shen, et al.
Published: (2025-05-01) -
The correlation of HLA-A in Thai EGFR-mutated advanced non-small cell lung cancer, outcome, and tumor microenvironment
by: Nicha Zungsontiporn, et al.
Published: (2025-08-01) -
Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models
by: Ilaria Marrocco, et al.
Published: (2021-03-01)